» Articles » PMID: 11427626

The Incidence of Biopsy-proven Glomerulonephritis in Australia

Overview
Date 2001 Jun 28
PMID 11427626
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is limited population-based epidemiological data on renal disease. An insight into the spectrum of clinically significant glomerulonephritis can be obtained from renal biopsy diagnoses. This is a descriptive report of biopsy-proven glomerulonephritis within a defined population.

Methods: A retrospective review of the pathology reports of all native renal biopsies performed in the Australian state of Victoria in 1995 and 1997 was undertaken. Trends in the average annual age- and sex-specific incidence rates for biopsy-proven glomerulonephritis were calculated. Comparisons were made with the incidence of end-stage renal disease due to glomerulonephritis confirmed on renal biopsy.

Results: The most common glomerulonephritides in adults are IgA disease, focal glomerulosclerosis, lupus nephritis and vasculitis, and in children are lupus nephritis, focal glomerulosclerosis, IgA disease and minimal change disease. A male predominance is seen for all glomerulonephritides, except lupus nephritis, in both adults and children. An increase in incidence of disease with age, particularly in males, is seen for vasculitis and focal glomerulosclerosis. The most common glomerulonephritides on renal biopsy are reflected in the most common causes of end-stage renal disease due to glomerulonephritis.

Conclusions: This review has provided population-based descriptive epidemiological data on clinically significant glomerulonephritis. This data provides important clues for further studies relating to the identification of risk factors for the various types of glomerulonephritis.

Citing Articles

Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.

Wang Y, Zhang L, Yuan L, Xie Q, Liu S, Hao C Ren Fail. 2024; 46(2):2381614.

PMID: 39039852 PMC: 11268216. DOI: 10.1080/0886022X.2024.2381614.


Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries.

Zaidi O, Du F, Tang Z, Bhattacharjee S, Pareja K BMC Nephrol. 2024; 25(1):136.

PMID: 38627670 PMC: 11021013. DOI: 10.1186/s12882-024-03555-5.


Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives.

Zhan H, Zhang X, Chen X, Cheng L, Wang X J Nanobiotechnology. 2024; 22(1):9.

PMID: 38169389 PMC: 10763010. DOI: 10.1186/s12951-023-02257-8.


The outcomes of patients with kidney failure due to focal segmental glomerulosclerosis (FSGS) in Australia and New Zealand: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA).

Bose B, Milanzi E, Pascoe E, Johnson D, Badve S PLoS One. 2023; 18(11):e0293721.

PMID: 37917639 PMC: 10621846. DOI: 10.1371/journal.pone.0293721.


Renal Biopsy for Diagnosis in Kidney Disease: Indication, Technique, and Safety.

Schnuelle P J Clin Med. 2023; 12(19).

PMID: 37835066 PMC: 10573674. DOI: 10.3390/jcm12196424.